Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / IL2RA



This biomarker is also known as:
  • IL-2R subunit alpha,
  • IL2R,
  • CD25,
  • TCGFR,
  • IDDM10,
  • p55,
  • IL-2 receptor subunit alpha,
  • CD25 antigen,
  • interleukin 2 receptor, alpha,
  • IL2-RA,
  • OTTHUMP00000019031,
  • TAC antigen,
  • IL-2-RA,
  • interleukin-2 receptor subunit alpha,

View in BioMuta


The interleukin 2 receptor exists in three forms which differ in their ability to bind interleukin 2. The low affinity form of the receptor is a monomer of IL2RA, the alpha subunit. The alpha/beta subunit heterodimer, formed by IL2RA and IL2RB, is an intermediate affinity form. The alpha/beta/gamma heterotrimer formed by IL2RA, IL2RB, and IL2RG is the high affinity form. IL2RA is normally an integral membrane protein, although soluble IL2RA has been isolated. There are known alternately-spliced versions of IL2RA mRNAs, but their functions are unknown. Mutations in the IL2RA gene are associated with diabetes mellitus insulin-dependent type 10 (IDDM10). Complications of IDDM10 can adversely affect the eyes, kidneys, nerves, and blood vessels.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


IL2RA is not a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.